These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10942236)

  • 1. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
    Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
    Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
    Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
    Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
    Moufarij MA; Sampath D; Keating MJ; Plunkett W
    Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
    Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
    Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
    Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.
    Molina-Arcas M; Marcé S; Villamor N; Huber-Ruano I; Casado FJ; Bellosillo B; Montserrat E; Gil J; Colomer D; Pastor-Anglada M
    Leukemia; 2005 Jan; 19(1):64-8. PubMed ID: 15510196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.
    König A; Menzel T; Lynen S; Wrazel L; Rosén A; Al-Katib A; Raveche E; Gabrilove JL
    Leukemia; 1997 Feb; 11(2):258-65. PubMed ID: 9009090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
    Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
    Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.
    Hewamana S; Lin TT; Jenkins C; Burnett AK; Jordan CT; Fegan C; Brennan P; Rowntree C; Pepper C
    Clin Cancer Res; 2008 Dec; 14(24):8102-11. PubMed ID: 19088025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.
    Adams DJ; Levesque MC; Weinberg JB; Smith KL; Flowers JL; Moore J; Colvin OM; Silber R
    Leukemia; 2001 Dec; 15(12):1852-9. PubMed ID: 11753605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
    Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
    Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
    Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
    Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
    Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine.
    Crassini K; Stevenson WS; Mulligan SP; Best OG
    Leuk Lymphoma; 2015; 56(12):3407-17. PubMed ID: 25804768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
    Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
    Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.
    Carew JS; Nawrocki ST; Xu RH; Dunner K; McConkey DJ; Wierda WG; Keating MJ; Huang P
    Leukemia; 2004 Dec; 18(12):1934-40. PubMed ID: 15483672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SYNERGISTIC ACTIVITY OF DEGUELIN AND FLUDARABINE IN PRIMARY CELLS FROM CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) AND IN A CLL MURINE MODEL].
    Vargas Núñez JA
    An R Acad Nac Med (Madr); 2014; 131(2):441-56. PubMed ID: 27400564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
    Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
    Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.
    Faria JR; Yamamoto M; Faria RM; Kerbauy J; Oliveira JS
    Braz J Med Biol Res; 2006 Mar; 39(3):327-33. PubMed ID: 16501812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.
    Martinez-Lostao L; Briones J; Martinez-Gallo M; Forné I; Sierra J; Rodriguez-Sanchez JL; Juarez C
    Leuk Lymphoma; 2004 Nov; 45(11):2307-14. PubMed ID: 15512822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.